NCT04337970View on ClinicalTrials.gov

Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

April 6, 2020

Primary Completion Date

May 23, 2025

Study Completion Date

May 23, 2025

Conditions
Kidney CancerRenal Cell CarcinomaUnresectable Renal Cell CarcinomaMetastatic Renal Cell Carcinoma
Interventions
DRUG

Talazoparib

"Dose Level 1: 0.5 mg PO daily Dose Level 2: 0.75 mg PO daily Dose Level 3: 1 mg PO daily~Phase II: MTD to be determined."

DRUG

Axitinib

5 mg PO BID

Trial Locations (7)

10065

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York

10604

Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison

11553

Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale

11725

Memorial Sloan Kettering Cancer Center @ Commack (Limited Protocol Activities), Commack

07920

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge

07748

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown

07645

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT04337970 - Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer | Biotech Hunter | Biotech Hunter